Concomitant use of combined hormonal contraceptives and antifibrinolytic agents for the management of heavy menstrual bleeding: A practice pattern survey.

ABSTRACT:

Introduction

Concomitant antifibrinolytic agents and combined hormonal contraceptives (CHC) have been anecdotally used to manage refractory heavy menstrual bleeding (HMB). Yet, there remains uncertainty among clinicians regarding the safety of this therapeutic option as concomitant CHC is listed as a contraindication to tranexamic acid use in the United States.

Aim

To describe current treatment practices and physician-reported safety and effectiveness of concomitant antifibrinolytics and CHCs.

Methods

We surveyed clinician members of the Hemostasis and Thrombosis Research Society and the Foundation of Women and Girls with Blood Disorders using a web-based survey. We also shared the survey link on Twitter.

Results

Of the 224 respondents who completed the survey,

SUBMITTER: Lim MY 

PROVIDER: S-EPMC8691851 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature